A case series on immunotherapy for leprosy reactions

Authors

  • Manjula Thakur Department of Dermatology, Chhattishgarh Institute of Medical Sciences, Bilaspur, Chhattishgarh, India
  • Atul Dilip Mohankar Department of Dermatology, Chhattishgarh Institute of Medical Sciences, Bilaspur, Chhattishgarh, India
  • Jyoti Prakash Swain Department of Dermatology, Chhattishgarh Institute of Medical Sciences, Bilaspur, Chhattishgarh, India

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20241205

Keywords:

Lepra reactions, Multidrug therapy, Immunotherapy

Abstract

Leprosy is a chronic granulomatous disease caused by mycobacterium leprae. As a result of immunological alterations evoked by organism, patients suffer from acute inflammatory episodes known as leprosy reactions, which can continue to occur before, during and after stoppage of therapy and are a cause of concern for the resulting morbidity. Understanding the beneficial effects of immunotherapy with chemotherapy will help in reducing reactions as well the duration of treatment. Five untreated patients of middle age with MI=0 was enrolled in our study who were presented with lepra reactions started on Multi-drug therapy (MDT) and then sent for BCG vaccination. Patients were evaluated monthly for clinical improvement 60% of patients showed improvement within 3 to 4 months whereas 40% patient showed improvement in 7 to 8 months of immunotherapy. Despite of available effective MDT, persisting viable organisms as well as persisting clinical activity are significant problems in leprosy patients. Immunotherapy combined with chemotherapy is good and more promising options to overcome these problems.

Metrics

Metrics Loading ...

References

World Health Organisation Weekly Epidemiological Record. 2008:83(33):293-300.

Van Brakel WH, Nicholls PG, Das L, Barkataki P, Suneetha SK, Jadhav RS, et al. The INFIR Cohort Study: Investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Lepr Rev. 2005;76:14-34.

Katoch K. Immunotherapy of leprosy. Indian J Lepr. 1996;68(4):349-61.

Sehgal VN, Sardana K, Immunoprophylaxis of leprosy: Current status and future prospects. Indian J Dermatol Venereol Leprol. 2007;73:71-2.

Sehgal VN, Sardana K. Lepra vaccine: Misinterpreted myth. Int J Dermatol. 2006;45:164-7.

Setia MS, Steinmaus C, Ho CS, Rutherford GW. The role of BCG in prevention of leprosy: A meta-analysis. Lancet Infect Dis. 2006;6:162-70.

Katoch K, Leprosy Vaccines and Immunotherapy. In: Kar H.K, Kumar B. IAL Textbook of Leprosy, 1st ed. Jaypee Brothers Medical Publishers Ltd. 2010: 410-417.

Fernandez JMM. Use of BCG in Immunoprophylaxsis of leprosy. Lepr Rev. 2005;76:127-43.

Convit J, Pinnardi ME, Rodriguez OC, Ulrich M, Avila JL, Goihman M. Elimination of Mycobacterium Leprae by other mycobacteria. Clin Exp Immunol. 1974;17(2):821-6.

Sharma P, Mukherjee R, Talwar P, Sarathchandra KG, Walia R, Parida SK, et al. Immunoprophylactic effects of anti-leprosy vaccine in household contacts of leprosy patients: clinical field trials with follow up of 8-10 years. Lepr Rev. 2005,76(2):127-43.

Gupte MD, Vallishayee RS, Ananaathramanan DS, Nagaraju B, Sreevatsa, Balasubramanyam S, et al. Comparative leprosy vaccine trial in south India. Indian J Lepr. 1998;70(4):369-87.

Downloads

Published

2024-04-30

How to Cite

Thakur, M., Mohankar, A. D., & Swain, J. P. (2024). A case series on immunotherapy for leprosy reactions. International Journal Of Community Medicine And Public Health, 11(5), 2041–2043. https://doi.org/10.18203/2394-6040.ijcmph20241205

Issue

Section

Case Series